Fig. 5
The anti-tumor effect of ibrutinib in vivo. (a) U87 cells (1× 106 cells per mouse) were subcutaneously injected into nude mice. The mice were treated with ibrutinib daily for 15 days. Subsequently, the mice were sacrificed and tumors were collected. Representative tumors isolated from the control and ibrutinib treated groups. (b) After ibrutinib treatment, the mean tumor volumes were assessed at the indicated days. (c-d) The Ki-67 and cleaved caspase-3 immunohistochemistry staining of U87 xenografts. The positive numbers of cells were counted and normalized to the control group. These data are presented as the means ± SEM of three independent experiments. (e) Representative images of H&E staining of coronal sections from mouse brains with orthotopic tumors. (f) The survival of mice with tumors derived from the vehicle or ibrutinib-treated groups was measured by Kaplan-Meier survival curves